Pay in 4 interest-free payments of $5.89 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
The trial program has evolved from glycemic-safety and outcomes studies in T2D (the LEADER, SUSTAIN-6, REWIND, EXSCEL, and PIONEER 6 era [10][13], [19]), to outcomes trials in expanded populations including obesity without diabetes (SELECT [3]), HFpEF with obesity (SUMMIT [5], with a companion semaglutide program in STEP-HFpEF [20], [21]), CKD (FLOW [22]), and an active-comparator setting (SURPASS-CVOT [6])
It also stimulates the formation of healthy red blood cells, making it useful in treating megaloblastic anemia caused by vitamin B12 deficiency
Five doses of cagrilintide were examined (0.3, 0.6, 1.2, 2.4, or 4.5 mg) compared to a single dose of liraglutide (3.0 mg) or volume-matched placebo for 6 placebo groups
Medical spending of the US elderly: medical spending of the US elderly
GLP-1 ( )
US$ 28.89
US$ 26.74
US$ 24.44
US$ 22.41
US$ 27.05
